ABSTRACT OBJECTIVES This study assessed clinical events and patient-reported chest pain 2 years after treatment of all-comers with Resolute Integrity zotarolimus-eluting stents (Medtronic Vascular, Santa Rosa, California) and Promus Element everolimus-eluting stents (Boston Scientific, Natick, Massachusetts).
In the presence of very low rates of traditional clinical endpoints following percutaneous coronary interventions (PCIs) with novel DES (4-6), there is growing interest in the assessment of patientreported chest pain-the principal anginal symptom and main trigger of repeat cardiac assessment despite a successful PCI (7, 8) . Moreover, long-lasting absence of chest pain determines to a great extent the "patient satisfaction" with PCI. Therefore, in the present 2-year analysis of the DUTCH PEERS allcomers population, we investigated both clinical event rates and patient-reported chest pain following treatment with Resolute Integrity ZES and Promus Element EES.
METHODS STUDY DESIGN, PATIENTS, AND PROCEDURES.
The DUTCH PEERS trial has previously been described in detail (4). In brief, DUTCH PEERS is a multicenter, prospective, randomized, single-blinded, investigator-initiated trial in an all-comers patient popula- procedural, and angiographic characteristics of both
DUTCH PEERS 2 Years: Adverse Events and Chest Pain study groups are summarized in Table 1 An exploratory subgroup analysis revealed no significant between-stent difference in TVF at 2 years across various subgroups (Figure 2 ). In addition, there was also no significant difference in various event rates between 1-and 2-year follow-up ( Table 3 ). None of the 9 patients who had developed longitudinal stent deformation in Promus Element EES during the index PCI procedure experienced an adverse clinical event during the second year of follow-up, although DAPT was discontinued after 12 months in all but 1 patient, who continued DAPT at physician discretion (Online Table 1 ).
The incidence of definite-or-probable stent thrombosis was 1.1% for both DES at 2-year follow- Table 2 ). Values are n, mean AE SD, or n (%). *Of 903 patients in the zotarolimus-eluting stent group and 905 patients in the everolimus-eluting stent group. †Of 903 patients in the zotarolimus-eluting stent group and 902 patients in the everolimus-eluting stent group. ‡Including chronic total occlusion, but not grafts or in-stent restenosis.
ACC/AHA ¼ American College of Cardiology/American Heart Association; CAD ¼ coronary artery disease; EES ¼ everolimus-eluting stent(s); RVD ¼ reference vessel diameter; ZES ¼ zotarolimus-eluting stent(s).
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arms reported an increase and 11.6% and 9.9% a decrease (p ¼ 0.30). Restricting the analysis of chest pain score at 1 and 2 years to patients who provided chest pain information at both times (Online Figure 2) led to results that were similar to findings in all responding patients at the individual times of follow-up ( Figures 4A and 4B ).
DISCUSSION
At 2-year follow-up of the DUTCH PEERS trial, the incidence of the primary endpoint TVF was low and similar in both stent arms. The rates of cardiac death, target vessel-related MI, and clinically-indicated TVR (i.e., the individual components of TVF), were also low and similar. In addition, despite enrollment of an all-comers population that included many high-risk patients and complex lesions, the incidence of very late stent thrombosis was extremely low. None of the few patients who initially had developed longitudinal stent deformation in Promus Element arm experienced a very late clinical event after cessation of DAPT.
At 1-and 2-year follow-up, >80% of patients in both stent arms were free from chest pain. In addition, >87% were either symptom-free or experienced chest pain only at the very maximal level of physical exertion, in that the pain did not limit the daily activities of this large group of patients.
PREVIOUS DES TRIALS WITH THE EXAMINED STENTS.
The present analysis from the DUTCH PEERS ran- Values are n (%). *Primary target vessel failure is a composite of cardiac death, target vessel-related myocardial infarction, or clinically-indicated target vessel revascularization. †Target lesion failure is a composite of cardiac death, target vessel-related myocardial infarction, or clinically-indicated target lesion revascularization. ‡Major adverse cardiac events is a composite endpoint of all-cause death, any myocardial infarction, emergent coronary artery bypass surgery, or clinically-indicated target lesion revascularization. §Patient-oriented composite endpoint is a composite of all-cause death, any myocardial infarction, or any revascularization.
CI ¼ confidence interval; other abbreviations as in Table 1 .
Sen et al. CHEST PAIN FOLLOWING PCI. Chest pain, the principal symptom of angina pectoris, is the main trigger for patients to consult medical professionals following a successful PCI procedure, and it is frequently associated with further cardiac assessment and increased costs (8) . The prevalence and recurrence of angina pectoris after coronary revascularization had previously been investigated in randomized studies that compared balloon angioplasty with coronary bypass surgery (22, 23) or with PCI, using bare-metal stents (24, 25) . However, randomized trials with DES were mostly focused on device-oriented endpoints (26) . Nowadays, there is a growing interest in the assessment of angina pectoris following the implantation of novel DES and bioresorbable scaffolds (7). But so far, there is a lack of published data In the DUTCH PEERS trial, there was no difference in chest pain between the 2 stent arms at both 1-and 2-year follow-up. More than 80% of our patients were entirely free from chest pain. This rate is similar to or higher than the prevalence of angina in several studies with bare-metal stents or DES, reporting 66%
to 79% of the patients to be angina-free at 1 year (7, (27) (28) (29) (30) . However, none of these studies applied the highly-deliverable DES that were used in DUTCH Figure 1 . Values are % (n/N) or % difference (95% CI). Analyses were performed among survivors of the first year of follow-up who did not experience the respective adverse event during 1-year follow-up. *Target lesion failure is a composite of cardiac death, target vessel-related myocardial infarction, or clinically-indicated target lesion revascularization. †Primary endpoint target vessel failure is a composite of cardiac death, target vessel-related myocardial infarction, or clinically-indicated target vessel revascularization. ‡Major adverse cardiac events is a composite of all-cause death, any myocardial infarction, emergent coronary artery bypass surgery, or clinically-indicated target lesion revascularization. §Patient-oriented composite endpoint is a composite of all-cause death, any myocardial infarction, or any revascularization.
Abbreviations as in Tables 1 and 2 .
Sen et al. number of questions, which might sometimes have a negative effect on the overall response rate of a study (32) .
In the present study, we did not assess angina, but we scored the patient-reported chest pain in relation to the individual range of physical activities of a patient. Although this approach does not attempt to distinguish between angina and atypical chest pain, it tackles the key issue of "patient satisfaction," which is greatly independent of the classification of chest pain into angina or atypical chest pain (26) . We 
CONCLUSIONS
During the second year of follow-up, the incidence of adverse clinical endpoints remained similar and low for both DES. The vast majority of patients were free from chest pain after 1 and 2 years. 
